New age of biological therapies in paediatric rheumatology

Area of Science:

• Paediatric Rheumatology
• Immunology
• Pharmacology

Background:

• Paediatric rheumatic diseases often stem from immune system dysregulation.
• Biologic drugs target specific molecules in cytokine signaling and cell interactions.
• Significant advancements in treating rheumatic diseases, especially juvenile idiopathic arthritis (JIA), have occurred in the last 15 years.

Purpose of the Study:

• To review evidence on biologic drug use in systemic JIA, juvenile dermatomyositis, and juvenile systemic lupus erythematosus.
• To highlight novel therapeutic agents under investigation for paediatric rheumatic diseases.
• To discuss the evolving treatment landscape aiming for inactive disease and minimal long-term damage.

Main Methods:

• Review of recent clinical trial evidence for biologic drugs.
• Inclusion of data on novel agents in development.
• Emphasis on the role of multicentre controlled clinical trials and international drug registries for safety monitoring.

Main Results:

• Biologic therapies have revolutionized treatment, making inactive disease achievable for many paediatric rheumatic conditions.
• Systemic JIA, juvenile dermatomyositis, and juvenile systemic lupus erythematosus have seen significant therapeutic progress.
• Emerging novel agents promise to expand future treatment options.

Conclusions:

• Biologic drugs represent a major therapeutic advance in paediatric rheumatology.
• Well-designed clinical trials and long-term safety monitoring are crucial for developing new treatments.
• The goal of achieving inactive disease and preventing long-term damage is increasingly attainable.